학술논문

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins
Document Type
Article
Source
In Atherosclerosis Plus March 2024 55:55-62
Subject
Language
ISSN
2667-0895